Anexigen is a San Diego-based biotechnology company developing novel methods and compositions to combat existing and burgeoning antimicrobial threats. Antibiotic overuse and the rapid evolution of microbial pathogens has led to a staggering level of multi-drug resistant bacterial infections; by 2050, drug-resistant organisms are estimated to cause 300 million deaths and $100 trillion in economic loss. Anexigen is addressing the antimicrobial drug-resistance crisis by leveraging our proprietary Surface Localized Antimicrobial DisplaY (SLAY) platform. Our technology enables functional screening of DNA-encoded peptide-based libraries directly on any Gram-negative pathogen to quickly identify novel antibiotic chemical scaffolds. The composition of the library can be readily tailored for chemical diversity and screened against any relevant bacterial species for screening, the platform has the potential to rapidly identify novel antibacterial agents with activity against drug-resistant bacteria of biomedical interest.